Tissue Regenix appoints VP for US subsidiary
TISSUE Regenix, the regenerative medical devices company, has appointed Tim Buechner as vice president of operations for its USA subsidiary, Tissue Regenix Wound Care Inc.
He will work with Greg Bila to lead the development and expansion of Tissue Regenix’s operations in the United States.
Buechner joins Tissues Regenix most recently from KCI where he was senior director of commercial and sales operations.
In the past, he has held positions with United Parcel Service, the Veteran’s Administration and the United States Air Force. He has managed major organisational initiatives and has extensive experience with developing new business units and processes.
York-based Tissue Regenix is currently establishing a new head office in San Antonio to facilitate the next phase of its expansion which will see the company collaborating with more research and clinical partners to expand the range of treatments using the dCELL process.
Buechner will be responsible for developing an agile infrastructure for the organisation that is capable of supporting the needs of the business.
Tissue Regenix Wound Care Inc was established in November 2012 and has made a series of senior appointments from across the USA healthcare sector to build an experienced team to lead the company’s development.
The first phase of this plan has seen Tissue Regenix, in June, sign a partnership with Community Tissue Services (CTS), the second largest tissue bank in the USA, to develop dCELL dermis products to target the wound care market.
The company’s dCELL technology platform is used to treat wounds and help prevent rejection by the body.
Greg Bila, president Tissue Regenix USA Inc, said: “We are delighted Tim has joined Tissue Regenix at this important point in our development. Since we established the USA business just eight months ago, we have made significant progress and the partnership with CTS enables us to move the business forward into full commercialisation, and use dCELL to develop dermis treatments for use in skin graft operations.
“We are confident that with Tim’s experience and contacts within the US healthcare sector he will play a valuable role in opening up new commercialisation partnerships for Tissue Regenix.”
Antony Odell, managing director of Tissue Regenix Group, added: “Tim joins a strong management team who are driving Tissue Regenix’s business growth and partnership development programme in the USA. Whilst we only established Tissue Regenix Wound Care Inc in November, we have worked for around three years with research partners at Yale University developing treatments for USA and global markets. Our latest partnership with CTS to produce dermis skin-grafts, plus the work with Yale on vascular patches (which have already achieved European CE marking) and the very promising work on heart valves with the Pontifical University of Parana means we are at an advanced stage in developing a range of treatments using dCELL technology, giving access to markets worth hundreds of millions of dollars.”
